- Home
- ABL vs TYRA Comparison
ABL vs TYRA Comparison
Compare ABL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- TYRA
- Stock Information
- Founded
- ABL 2004
- TYRA 2018
- Country
- ABL United States
- TYRA United States
- Employees
- ABL N/A
- TYRA N/A
- Industry
- ABL Investment Managers
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- TYRA Health Care
- Exchange
- ABL Nasdaq
- TYRA Nasdaq
- Market Cap
- ABL 723.0M
- TYRA 812.7M
- IPO Year
- ABL N/A
- TYRA 2021
- Fundamental
- Price
- ABL $7.72
- TYRA $14.00
- Analyst Decision
- ABL Strong Buy
- TYRA Strong Buy
- Analyst Count
- ABL 4
- TYRA 5
- Target Price
- ABL $14.38
- TYRA $31.00
- AVG Volume (30 Days)
- ABL 443.3K
- TYRA 219.5K
- Earning Date
- ABL 11-07-2024
- TYRA 11-07-2024
- Dividend Yield
- ABL N/A
- TYRA N/A
- EPS Growth
- ABL N/A
- TYRA N/A
- EPS
- ABL N/A
- TYRA N/A
- Revenue
- ABL $102,407,324.00
- TYRA N/A
- Revenue This Year
- ABL $70.90
- TYRA N/A
- Revenue Next Year
- ABL $65.20
- TYRA N/A
- P/E Ratio
- ABL N/A
- TYRA N/A
- Revenue Growth
- ABL 77.68
- TYRA N/A
- 52 Week Low
- ABL $7.07
- TYRA $11.24
- 52 Week High
- ABL $13.25
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ABL 41.66
- TYRA 32.68
- Support Level
- ABL $7.63
- TYRA $14.65
- Resistance Level
- ABL $8.09
- TYRA $15.55
- Average True Range (ATR)
- ABL 0.33
- TYRA 0.72
- MACD
- ABL 0.01
- TYRA 0.02
- Stochastic Oscillator
- ABL 42.25
- TYRA 3.12
About ABL Abacus Life Inc.
Abacus Life Inc is a vertically integrated alternative asset manager specializing in investing in life insurance products throughout the lifecycle of a life insurance policy.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).